Alcon Surgical Inc. has agreed to indemnify Lifecore Biomedical Inc. (NASDAQ:LCBM) fromany patent infringements that might arise from its activities under the supply agreementfor Lifecore’s opthalmic sodium hyaluronate.

Alcon, Lifecore’s largest customer over several years, accounts for a significantportion of total revenues. The indemnification will eliminate a key risk factor forLifecore’s investors, ensuring that Lifecore’s revenue stream should not beinterrupted by patent infringement claims directed to sodium hyaluronate used inAlcon’s VISCOAT opthalmic viscosurgery product.

Lifecore develops, manufactures and markets sterile devices for surgical applications.

No Comments